179 related articles for article (PubMed ID: 26769860)
1. Biokinetic Modeling and Dosimetry for Optimizing Intraperitoneal Radioimmunotherapy of Ovarian Cancer Microtumors.
Palm S; Bäck T; Haraldsson B; Jacobsson L; Lindegren S; Albertsson P
J Nucl Med; 2016 Apr; 57(4):594-600. PubMed ID: 26769860
[TBL] [Abstract][Full Text] [Related]
2. Model of Intraperitoneal Targeted α-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes.
Palm S; Bäck T; Lindegren S; Hultborn R; Jacobsson L; Albertsson P
J Nucl Med; 2018 Apr; 59(4):646-651. PubMed ID: 29175984
[TBL] [Abstract][Full Text] [Related]
3. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
Behr TM; Sgouros G; Stabin MG; Béhé M; Angerstein C; Blumenthal RD; Apostolidis C; Molinet R; Sharkey RM; Koch L; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
[TBL] [Abstract][Full Text] [Related]
5. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings.
Behr TM; Béhé M; Sgouros G
Cancer Biother Radiopharm; 2002 Aug; 17(4):445-64. PubMed ID: 12396708
[TBL] [Abstract][Full Text] [Related]
6. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
7. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
[TBL] [Abstract][Full Text] [Related]
8. Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with
Bäck T; Chouin N; Lindegren S; Kahu H; Jensen H; Albertsson P; Palm S
J Nucl Med; 2017 Apr; 58(4):598-604. PubMed ID: 27688477
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
10. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.
Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2006 Aug; 47(8):1342-50. PubMed ID: 16883015
[TBL] [Abstract][Full Text] [Related]
11. Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.
Cederkrantz E; Andersson H; Bernhardt P; Bäck T; Hultborn R; Jacobsson L; Jensen H; Lindegren S; Ljungberg M; Magnander T; Palm S; Albertsson P
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):569-76. PubMed ID: 26460999
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
Andersson H; Cederkrantz E; Bäck T; Divgi C; Elgqvist J; Himmelman J; Horvath G; Jacobsson L; Jensen H; Lindegren S; Palm S; Hultborn R
J Nucl Med; 2009 Jul; 50(7):1153-60. PubMed ID: 19525452
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal α-Emitting Radioimmunotherapy with
Hallqvist A; Bergmark K; Bäck T; Andersson H; Dahm-Kähler P; Johansson M; Lindegren S; Jensen H; Jacobsson L; Hultborn R; Palm S; Albertsson P
J Nucl Med; 2019 Aug; 60(8):1073-1079. PubMed ID: 30683761
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.
Andersson H; Palm S; Lindegren S; Bäck T; Jacobsson L; Leser G; Horvath G
Anticancer Res; 2001; 21(1A):409-12. PubMed ID: 11299770
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
17. Use of Monte Carlo simulations with a realistic rat phantom for examining the correlation between hematopoietic system response and red marrow absorbed dose in Brown Norway rats undergoing radionuclide therapy with (177)Lu- and (90)Y-BR96 mAbs.
Larsson E; Ljungberg M; Martensson L; Nilsson R; Tennvall J; Strand SE; Jonsson BA
Med Phys; 2012 Jul; 39(7):4434-43. PubMed ID: 22830776
[TBL] [Abstract][Full Text] [Related]
18. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
Deshayes E; Ladjohounlou R; Le Fur P; Pichard A; Lozza C; Boudousq V; Sevestre S; Jarlier M; Kashani R; Koch J; Sosabowski J; Foster J; Chouin N; Bruchertseifer F; Morgenstern A; Kotzki PO; Navarro-Teulon I; Pouget JP
J Nucl Med; 2018 Aug; 59(8):1234-1242. PubMed ID: 29674421
[TBL] [Abstract][Full Text] [Related]
19. [Kinetics and dosimetry of monoclonal antibody MAb-170: evaluation of possibilities for intraperitoneal radioimmunotherapy].
Alexander C; Holländer M; Schmidt W; Kirsch CM
Nuklearmedizin; 2001 Dec; 40(6):207-14. PubMed ID: 11797509
[TBL] [Abstract][Full Text] [Related]
20. Theoretical estimation of absorbed dose to organs in radioimmunotherapy using radionuclides with multiple unstable daughters.
Hamacher KA; Sgouros G
Med Phys; 2001 Sep; 28(9):1857-74. PubMed ID: 11585217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
